Deniel is the Editor of Last Financier, a commentary and subscription-based investment newsletter focused on the latest market trends and actionable trades in high-tech and healthcare. His investment research, with notable calls in 3D Printing, communication technologies and emerging oncology names, has been syndicated throughout leading financial media platforms across the web.
Recent Articles By The Author
Sentiment for Advaxis Back to Bullish With Broadfin and Inovio Deal
Advaxis back on investor good books after Broadfin healthcare fund doubled their position after stock's 40% decline
Advaxis Receives Vote of Confidence From Hedge Fund Adage Capital
Adage Capital averaged their Advaxis position up at a price 150% higher than their last offering. What is the hedge fund seeing in the immunotherapy company?
Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro
Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.
Advaxis Surges Higher on Additional Institutional Interest
Advaxis stock rallied after a private placement showed added fund participation. Read how this move has rebutted the short thesis.
Ebix Short Thesis Undermined by IRS Audit Investigation Resolution
Insurance technology provider Ebix is one of the most shorted stocks on the Nasdaq, but a positive resolution to an IRS investigation may soon change minds.
3 Health Care Stock Picks for 2015 in the Age of Obamacare
Private exchanges will prove to be beneficiaries of the health care shift.
Activist Fund Targets Ebix to Boost Board Oversight and Unlock Value
Barington Capital sent Ebix a letter to call for improved board oversight. Could this be the catalyst the market needs to realize Ebix's value?